Published by Frank Prenesti on 1st October 2018
(Sharecast News) - AstraZeneca said it had agreed a $200m deal with Germany's Cheplapharm Arzneimittel for the European commercial rights to Atacand and Atacand Plus heart and hypertension treatments.
URL: http://www.digitallook.com/dl/news/story/28072598/...